Oncolys BioPharma Inc.
4588・Growth Market・Pharmaceuticals
Business
Oncolys BioPharma Inc. is a biotech company established in 2004 that specializes exclusively in virus-based drug discovery. Its pipeline is built around two pillars: the "Oncolytic Virus Therapy for Cancer" area, centered on the oncolytic virus OBP-301 (esophageal cancer) and the next-generation oncolytic virus OBP-702 (pancreatic cancer, etc.), and the "Severe Viral Infectious Disease" area, centered on the LINE-1 inhibitor OBP-601 (censavudine) (intractable neurological disease) and the antiviral infection treatment OBP-2011. In December 2025, the company completed the domestic manufacturing and marketing approval application for OBP-301, and is advancing a transition from its conventional license-based model to a hybrid business model combining it with a pharmaceutical-company-type model. The company is listed on the Growth Market of the Tokyo Stock Exchange.
Business Model
Historically, the company adopted a licensing model in which pipeline assets were developed to a certain stage before being out-licensed to pharmaceutical companies in exchange for upfront payments, milestones, and royalties. OBP-601 (censavudine) has been licensed to Transposon (a licensing agreement worth over $300 million in total), and Taiwan rights for OBP-301 have been licensed to Medigen. Going forward, the company will pursue in parallel a pharmaceutical company model that includes domestic in-house sales of OBP-301 (a sales partnership with Fujifilm Toyama Chemical, with milestones of up to ¥1,700 million), aiming to diversify its revenue sources.
Company Strengths
Completed the marketing authorization application to the Ministry of Health, Labour and Welfare in December 2025 as a regenerative medical product for esophageal cancer treatment. Obtained designation as an orphan regenerative medical product in the same month. In addition to the SAKIGAKE designation (2019), the company has already received confirmation documents from PMDA for all review categories (clinical, non-clinical, quality, GCTP, and reliability), confirming progress in the review process.
In April 2025, a patent related to endoscopic administration of oncolytic adenovirus was granted in Japan (valid until May 2040). This patent provides broad rights covering not only OBP-301 and OBP-702 but also oncolytic adenoviruses of other companies, potentially functioning as a barrier to entry for competitors. The patent is also under examination in the US and Europe.
In the Phase 2 clinical trial conducted by Transposon Therapeutics for PSP and ALS, multiple efficacy signals were confirmed, including reductions in the neurodegeneration markers NfL and NfH, a reduction in the inflammatory biomarker IL-6, suppression of disease progression on the ALS Functional Rating Scale (ALSFRS-R), and approximately a 50% reduction in the rate of decline in vital capacity compared to placebo. The FDA has granted Fast Track designation for PSP (May 2024).
ENVALITH's Perspective
Performance Trend
Revenue over the past five fiscal years has moved as follows: ¥642 million (FY2021) → ¥976 million (FY2022) → ¥63 million (FY2023) → ¥31 million (FY2024) → ¥29 million (FY2025), remaining at an extremely low level after license income was recorded in FY2022. In the first quarter of FY2026 (ending December 2026), revenue was ¥3 million (versus zero in the same quarter of the previous year), and operating loss narrowed substantially to ¥420 million (from ¥785 million in the same quarter of the previous year). This narrowing was mainly attributable to cost reductions. While external uncertainties exist, such as a sharp rise in crude oil prices stemming from the closure of the Strait of Hormuz, R&D expenses remained at a high level of ¥245 million. Earnings guidance has not been disclosed.
Growth Strategy
Building on the domestic launch of OBP-301, the company aims to accelerate monetization of multiple pipelines through a hybrid model
The approval application was completed to the PMDA in December 2025, and a conformity investigation resulted in a "conformity" determination in April 2026. Sales partnership with Fujifilm Toyama Chemical and supply chain arrangements (GCTP-compliant) with Mitsui Warehouse Holdings have been established. Confirmation of 18-month stability for the formulation under the new prescription (February 2026) has also been completed, and the shipment framework for the first commercial lot is in place.
A distribution license agreement was concluded with Taiwan's Medigen Vaccine Biologics Corporation in December 2024. Following launch, the company expects to earn revenue from paid supply of the OBP-301 finished product and royalty income. In the United States, a joint Phase 2 clinical trial for gastric cancer with MSD (with costs shared equally) and a Phase 1 trial for esophageal cancer by the NRG Oncology group are underway, and the company aims to expand opportunities for additional licensing through the accumulation of clinical data.
Three trials are planned to commence during 2026: a PSP Phase 3 trial (planned to start in 2026 after completion of fundraising), an ALS Phase 2/3 trial (utilizing the Healey ALS Platform, planned to start in 2026), and an Alzheimer's disease Phase 2 trial (utilizing approximately $5 million in ADDF investment, planned to start in 2026). Milestone income associated with the achievement of each development event will directly impact the company's financial results.
Utilizing an AMED grant program, a research group in the Department of Gastroenterological Surgery at Okayama University plans to commence an investigator-initiated Phase 1 trial targeting pancreatic cancer in 2026. Strong antitumor effects through combination with a PD-L1 antibody have already been confirmed in a gemcitabine-resistant pancreatic cancer cell line mouse model. The company intends to nurture this as a next-generation pipeline while considering differentiation from OBP-301.
Last updated: July 17, 2026